help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hernberg-Ståhl, E.
Right arrow Articles by Monson, J. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hernberg-Ståhl, E.
Right arrow Articles by Monson, J. P.
The Journal of Clinical Endocrinology & Metabolism Vol. 86, No. 11 5277-5281
Copyright © 2001 by The Endocrine Society


Endocrine Care

Healthcare Consumption Decreases in Parallel with Improvements in Quality of Life during GH Replacement in Hypopituitary Adults with GH Deficiency

Elizabeth Hernberg-Ståhl, Anton Luger, Roger Abs, Bengt-Åke Bengtsson, Ulla Feldt-Rasmussen, Patrick Wilton, Björn Westberg, John P. Monson and the Kims International Board1 on behalf of the Kims Study Group

KIGS/KIMS Outcomes Research (E.H.-S., P.W., B.W.), Pharmacia AB, S-11287 Stockholm, Sweden; Department of Medicine III (A.L.), Division of Endocrinology and Metabolism, University of Vienna, 1090 Vienna, Austria; Department of Endocrinology (R.A.), University Hospital, B-2650 Antwerp, Belgium; Research Centre for Endocrinology and Metabolism (B.-Å.B.), Sahlgrenska University Hospital, S-41345 Göteborg, Sweden; Department of Endocrinology (U.F.-R.), Rigshospitalet, DK-2100 Copenhagen, Denmark; and Department of Medicine and Endocrinology (J.P.M.), St. Bartholomew’s Hospital, London EC1A 7BE, United Kingdom

Address all correspondence and requests for reprints to: Prof. J. P. Monson, Department of Medicine and Endocrinology, Division of General and Developmental Medicine, St. Bartholomew’s and the Royal London School of Medicine and Dentistry, St. Bartholomew’s Hospital, London EC1A 7BE, United Kingdom.

Abstract

The morbidity associated with GH deficiency (GHD) in adults is now well established. Furthermore, many controlled clinical trials have demonstrated the efficacy of GH replacement therapy. The aim of the present study was to determine whether the effects of GH replacement in adults are reflected in a reduced use of healthcare resources, in addition to improving quality of life (QoL). Data concerning visits to the doctor, number of days in hospital, and amount of sick leave were obtained from patients included in KIMS (Pharmacia International Metabolic Database), a large pharmacoepidemiological survey of hypopituitary adults with GHD, for 6 months before GH treatment and for 6–12 months after the start of treatment. Assistance required with normal daily activities was recorded at baseline and after 12 months of GH therapy. QoL (assessed using a disease-specific questionnaire, QoL-Assessment of GHD in Adults) and satisfaction with physical activity during leisure time were also assessed. For the total group (n = 304), visits to the doctor, number of days in hospital, and amount of sick leave decreased significantly (P < 0.05) after 12 months of GH therapy. Patients also needed less assistance with daily activities, although this was significant (P < 0.01) only for the men. QoL improved after 12 months of GH treatment (P < 0.001), and both the amount of physical activity and the patients’ satisfaction with their level of physical activity improved after 12 months (P < 0.001). In conclusion, GH replacement therapy, in previously untreated adults with GHD, produces significant decreases in the use of healthcare resources, which are correlated with improvements in QoL.




This article has been cited by other articles:


Home page
Eur J EndocrinolHome page
B. Saller, A. F Mattsson, P. H Kann, H. P Koppeschaar, J. Svensson, M. Pompen, and M. Koltowska-Haggstrom
Healthcare utilization, quality of life and patient-reported outcomes during two years of GH replacement therapy in GH-deficient adults - comparison between Sweden, The Netherlands and Germany.
Eur. J. Endocrinol., June 1, 2006; 154(6): 843 - 850.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
M. Iruthayanathan, Y.-H. Zhou, and G. V. Childs
Dehydroepiandrosterone Restoration of Growth Hormone Gene Expression in Aging Female Rats, in Vivo and in Vitro: Evidence for Actions via Estrogen Receptors
Endocrinology, December 1, 2005; 146(12): 5176 - 5187.
[Abstract] [Full Text] [PDF]


Home page
Eur J EndocrinolHome page
J. Bollerslev, J. Hallen, K. J Fougner, A. P. Jorgensen, C. Kristo, H. Fagertun, O. Gudmundsen, P. Burman, and T. Schreiner
Low-dose GH improves exercise capacity in adults with GH deficiency: effects of a 22-month placebo-controlled, crossover trial
Eur. J. Endocrinol., September 1, 2005; 153(3): 379 - 387.
[Abstract] [Full Text] [PDF]


Home page
J. Gerontol. A Biol. Sci. Med. Sci.Home page
S. M. Harman and M. R. Blackman
Hormones and Supplements: Do They Work?: Use of Growth Hormone for Prevention or Treatment of Effects of Aging
J. Gerontol. A Biol. Sci. Med. Sci., July 1, 2004; 59(7): B652 - B658.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
J. Svensson and B.-A. Bengtsson
Growth Hormone Replacement Therapy and Insulin Sensitivity
J. Clin. Endocrinol. Metab., April 1, 2003; 88(4): 1453 - 1454.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2001 by The Endocrine Society